Oswaldo Cruz Foundation

fiocruz.br

Total trials

41

Active

5

Phase 3

9

Total enrollment

46,958

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Yellow Fever vaccination1
BCG (Bacillus Calmette-Guérin) vaccine1
Oral Pre-Exposure Prophylaxis1
Doxycycline1
Lenacapavir long-acting1
Tenofovi-Emtricitabine (TDF/FTC)1

Next readouts

  • 2018-12
  • 2023-07-31
  • 2026-12
  • 2027-10
  • 2029-02

Top conditions

  • HIV Infections5
  • Schistosomiasis3
  • Hepatitis C3
  • Tuberculosis3
  • Liver Diseases2
  • Cervical Intraepithelial Neoplasia2
  • HIV Infection2
  • Schistosomiasis Mansoni2

Frequently asked questions about Oswaldo Cruz Foundation

How many clinical trials does Oswaldo Cruz Foundation have on ClinicalTrials.gov?
Oswaldo Cruz Foundation is listed as the lead sponsor on 41 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
How many of Oswaldo Cruz Foundation's trials are in Phase 3?
9 of Oswaldo Cruz Foundation's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does Oswaldo Cruz Foundation focus on?
Oswaldo Cruz Foundation's most-studied conditions on ClinicalTrials.gov are HIV Infections, Schistosomiasis, Hepatitis C, Tuberculosis, Liver Diseases.
When are Oswaldo Cruz Foundation's next clinical trial readouts?
Oswaldo Cruz Foundation has 5 upcoming primary-completion readouts tracked here; the soonest is “Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals”, expected around 2018-12.